1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Protocols	_	_	NNS	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	Induce	_	_	VB	_	_	_	_	_
4	Mature	_	_	JJ	_	_	_	_	_
5	EC	_	_	NNP	_	_	_	_	_
6	Phenotype	_	_	NN	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	well	_	_	RB	_	_	_	_	_
4	known	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	clinical	_	_	JJ	_	_	_	_	_
8	use	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	it	_	_	PRP	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	mandatory	_	_	JJ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	generate	_	_	VB	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	able	_	_	JJ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	show	_	_	VB	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	high	_	_	JJ	_	_	_	_	_
21	degree	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	commitment	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	requirement	_	_	NN	_	_	_	_	_
3	fulfills	_	_	VBZ	_	_	_	_	_
4	not	_	_	RB	_	_	_	_	_
5	only	_	_	RB	_	_	_	_	_
6	functional	_	_	JJ	_	_	_	_	_
7	issues	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	but	_	_	CC	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	safety	_	_	NN	_	_	_	_	_
12	ones	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	order	_	_	NN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	prevent	_	_	VB	_	_	_	_	_
18	teratoma	_	_	NN	_	_	_	_	_
19	formation	_	_	NN	_	_	_	_	_
20	after	_	_	IN	_	_	_	_	_
21	implantation	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	prerequisite	_	_	NN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	exploit	_	_	VB	_	_	_	_	_
7	iPSC-ECs	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	clinical	_	_	JJ	_	_	_	_	_
11	setting	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	development	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	defined	_	_	VBN	_	_	_	_	_
17	protocols	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	guide	_	_	VB	_	_	_	_	_
20	their	_	_	PRP$	_	_	_	_	_
21	differentiation	_	_	NN	_	_	_	_	_
22	into	_	_	IN	_	_	_	_	_
23	functional	_	_	JJ	_	_	_	_	_
24	endothelial	_	_	JJ	_	_	_	_	_
25	cells	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	ideal	_	_	JJ	_	_	_	_	_
3	induction	_	_	NN	_	_	_	_	_
4	protocol	_	_	NN	_	_	_	_	_
5	should	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	reproducible	_	_	JJ	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	easy	_	_	JJ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	perform	_	_	VB	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	relatively	_	_	RB	_	_	_	_	_
14	quick	_	_	JJ	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	order	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	allow	_	_	VB	_	_	_	_	_
19	yielding	_	_	VBG	_	_	_	_	_
20	an	_	_	DT	_	_	_	_	_
21	adequate	_	_	JJ	_	_	_	_	_
22	quantity	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	homogeneous	_	_	JJ	_	_	_	_	_
25	cells	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Current	_	_	JJ	_	_	_	_	_
2	induction	_	_	NN	_	_	_	_	_
3	strategies	_	_	NNS	_	_	_	_	_
4	include	_	_	VBP	_	_	_	_	_
5	embryonic	_	_	JJ	_	_	_	_	_
6	bodies	_	_	NNS	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	EB	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	generation	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	differentiation	_	_	NN	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	monolayers	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	co-culture	_	_	NN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	primary	_	_	JJ	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	4	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	IPSCs	_	_	NNS	_	_	_	_	_
2	tend	_	_	VBP	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	self-assemble	_	_	VB	_	_	_	_	_
5	into	_	_	IN	_	_	_	_	_
6	three-dimensional	_	_	JJ	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	3D	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	structures	_	_	NNS	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	EB	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	when	_	_	WRB	_	_	_	_	_
15	grown	_	_	VBN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	suspension	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	From	_	_	IN	_	_	_	_	_
2	EBs	_	_	NNP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	cell	_	_	NN	_	_	_	_	_
5	aggregates	_	_	NNS	_	_	_	_	_
6	encompassing	_	_	VBG	_	_	_	_	_
7	all	_	_	DT	_	_	_	_	_
8	three	_	_	CD	_	_	_	_	_
9	germ	_	_	NN	_	_	_	_	_
10	layers	_	_	NNS	_	_	_	_	_
11	develop	_	_	VBP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	afterwards	_	_	RB	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	within	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	positive	_	_	JJ	_	_	_	_	_
19	mesodermal	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	EB	_	_	NNP	_	_	_	_	_
22	cells	_	_	NNS	_	_	_	_	_
23	tend	_	_	VBP	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	form	_	_	VB	_	_	_	_	_
26	vascular	_	_	JJ	_	_	_	_	_
27	structures	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	method	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	affected	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	low	_	_	JJ	_	_	_	_	_
7	efficiency	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	1	_	_	CD	_	_	_	_	_
10	â€“	_	_	TO	_	_	_	_	_
11	5	_	_	CD	_	_	_	_	_
12	%	_	_	NN	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	slow	_	_	JJ	_	_	_	_	_
16	production	_	_	NN	_	_	_	_	_
17	rate	_	_	NN	_	_	_	_	_
18	;	_	_	:	_	_	_	_	_
19	however	_	_	RB	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	differentiation	_	_	NN	_	_	_	_	_
22	can	_	_	MD	_	_	_	_	_
23	be	_	_	VB	_	_	_	_	_
24	improved	_	_	VBN	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	adding	_	_	VBG	_	_	_	_	_
27	proper	_	_	JJ	_	_	_	_	_
28	growth	_	_	NN	_	_	_	_	_
29	factors	_	_	NNS	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	culture	_	_	NN	_	_	_	_	_
33	medium	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	approach	_	_	NN	_	_	_	_	_
3	involves	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	co-culture	_	_	NN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	primary	_	_	JJ	_	_	_	_	_
8	cell	_	_	NN	_	_	_	_	_
9	lines	_	_	NNS	_	_	_	_	_
10	able	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	induce	_	_	VB	_	_	_	_	_
13	iPSC-EC	_	_	NNP	_	_	_	_	_
14	differentiation	_	_	NN	_	_	_	_	_
15	toward	_	_	IN	_	_	_	_	_
16	mature	_	_	JJ	_	_	_	_	_
17	ECs	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	detail	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	Choi	_	_	NNP	_	_	_	_	_
5	et	_	_	FW	_	_	_	_	_
6	al.	_	_	FW	_	_	_	_	_
7	directed	_	_	VBN	_	_	_	_	_
8	hiPSCs	_	_	NNS	_	_	_	_	_
9	into	_	_	IN	_	_	_	_	_
10	mature	_	_	JJ	_	_	_	_	_
11	ECs	_	_	NNP	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	presence	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	OP9	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	mouse	_	_	NN	_	_	_	_	_
20	bone	_	_	NN	_	_	_	_	_
21	marrow	_	_	NN	_	_	_	_	_
22	stromal	_	_	NN	_	_	_	_	_
23	cell	_	_	NN	_	_	_	_	_
24	line	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	authors	_	_	NNS	_	_	_	_	_
3	speculated	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	regulate	_	_	VBP	_	_	_	_	_
8	iPSC	_	_	NN	_	_	_	_	_
9	induction	_	_	NN	_	_	_	_	_
10	via	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	paracrine	_	_	NN	_	_	_	_	_
13	signaling	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Monolayer	_	_	NN	_	_	_	_	_
2	differentiation	_	_	NN	_	_	_	_	_
3	holds	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	significantly	_	_	RB	_	_	_	_	_
6	higher	_	_	JJR	_	_	_	_	_
7	efficiency	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	depends	_	_	VBZ	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	external	_	_	JJ	_	_	_	_	_
12	factors	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	such	_	_	JJ	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	medium	_	_	JJ	_	_	_	_	_
17	constituents	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	showing	_	_	VBG	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	final	_	_	JJ	_	_	_	_	_
22	yield	_	_	NN	_	_	_	_	_
23	that	_	_	WDT	_	_	_	_	_
24	is	_	_	VBZ	_	_	_	_	_
25	still	_	_	RB	_	_	_	_	_
26	too	_	_	RB	_	_	_	_	_
27	low	_	_	JJ	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	view	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	clinical	_	_	JJ	_	_	_	_	_
33	applications	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	date	_	_	VB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	best	_	_	JJS	_	_	_	_	_
6	protocols	_	_	NNS	_	_	_	_	_
7	showing	_	_	VBG	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	highest	_	_	JJS	_	_	_	_	_
10	EC	_	_	NN	_	_	_	_	_
11	yields	_	_	NNS	_	_	_	_	_
12	were	_	_	VBD	_	_	_	_	_
13	developed	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	culturing	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	monolayer	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	hiPSCs	_	_	NNS	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	matrix-coated	_	_	JJ	_	_	_	_	_
23	culture	_	_	NN	_	_	_	_	_
24	plate	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	treating	_	_	VBG	_	_	_	_	_
28	them	_	_	PRP	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	different	_	_	JJ	_	_	_	_	_
31	molecules	_	_	NNS	_	_	_	_	_
32	or	_	_	CC	_	_	_	_	_
33	growth	_	_	NN	_	_	_	_	_
34	factors	_	_	NNS	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	a	_	_	DT	_	_	_	_	_
37	timed	_	_	VBN	_	_	_	_	_
38	fashion	_	_	NN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	order	_	_	NN	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	guide	_	_	VB	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	progressive	_	_	JJ	_	_	_	_	_
45	differentiation	_	_	NN	_	_	_	_	_
46	of	_	_	IN	_	_	_	_	_
47	hiPSCs	_	_	NNS	_	_	_	_	_
48	toward	_	_	IN	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	EC	_	_	NNP	_	_	_	_	_
51	lineage	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	context	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	GSK3	_	_	NNP	_	_	_	_	_
6	inhibitors	_	_	NNS	_	_	_	_	_
7	play	_	_	VBP	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	important	_	_	JJ	_	_	_	_	_
10	role	_	_	NN	_	_	_	_	_
11	among	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	set	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	molecules	_	_	NNS	_	_	_	_	_
16	necessary	_	_	JJ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	induce	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	differentiation	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	pluripotent	_	_	JJ	_	_	_	_	_
23	cells	_	_	NNS	_	_	_	_	_
24	into	_	_	IN	_	_	_	_	_
25	mature	_	_	JJ	_	_	_	_	_
26	ECs	_	_	NNP	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	particular	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	vascular	_	_	JJ	_	_	_	_	_
5	progenitors	_	_	NNS	_	_	_	_	_
6	derive	_	_	VBP	_	_	_	_	_
7	during	_	_	IN	_	_	_	_	_
8	human	_	_	JJ	_	_	_	_	_
9	development	_	_	NN	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	latero-posterior	_	_	JJ	_	_	_	_	_
12	mesoderm	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	specify	_	_	VB	_	_	_	_	_
3	mesoderm	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	Wnt	_	_	NN	_	_	_	_	_
6	signaling	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	which	_	_	WDT	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	activated	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	GSK3	_	_	NNP	_	_	_	_	_
13	inhibition	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	required	_	_	VBN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	view	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	authors	_	_	NNS	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	exploited	_	_	VBN	_	_	_	_	_
10	GSK3	_	_	NN	_	_	_	_	_
11	inhibitors	_	_	NNS	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	differentiate	_	_	VB	_	_	_	_	_
14	hiPSCs	_	_	NNS	_	_	_	_	_
15	into	_	_	IN	_	_	_	_	_
16	ECs	_	_	NNP	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_
18	Patsch	_	_	NNP	_	_	_	_	_
19	et	_	_	FW	_	_	_	_	_
20	al.	_	_	FW	_	_	_	_	_
21	exposed	_	_	VBD	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	monolayer	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	hiPSC	_	_	NN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	GSK3	_	_	NNP	_	_	_	_	_
28	inhibitor	_	_	NN	_	_	_	_	_
29	CHIR-99021	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	CHIR	_	_	NN	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	mesoderm	_	_	NN	_	_	_	_	_
36	inducer	_	_	NN	_	_	_	_	_
37	bone	_	_	NN	_	_	_	_	_
38	morphogenetic	_	_	JJ	_	_	_	_	_
39	protein	_	_	NN	_	_	_	_	_
40	4	_	_	CD	_	_	_	_	_
41	(	_	_	-LRB-	_	_	_	_	_
42	BMP4	_	_	NN	_	_	_	_	_
43	)	_	_	-RRB-	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	combination	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	two	_	_	CD	_	_	_	_	_
6	molecules	_	_	NNS	_	_	_	_	_
7	led	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	production	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	mature	_	_	JJ	_	_	_	_	_
13	ECs	_	_	NNP	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	relatively	_	_	RB	_	_	_	_	_
17	short	_	_	JJ	_	_	_	_	_
18	time	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	six	_	_	CD	_	_	_	_	_
21	days	_	_	NNS	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	80	_	_	CD	_	_	_	_	_
25	%	_	_	NN	_	_	_	_	_
26	efficiency	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	mesoderm	_	_	NN	_	_	_	_	_
4	induction	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	only	_	_	RB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	first	_	_	JJ	_	_	_	_	_
9	step	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	differentiation	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	second	_	_	JJ	_	_	_	_	_
3	part	_	_	NN	_	_	_	_	_
4	starts	_	_	VBZ	_	_	_	_	_
5	upon	_	_	IN	_	_	_	_	_
6	mesodermal	_	_	JJ	_	_	_	_	_
7	commitment	_	_	NN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	exposing	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	cells	_	_	NNS	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	factors	_	_	NNS	_	_	_	_	_
14	that	_	_	WDT	_	_	_	_	_
15	further	_	_	RBR	_	_	_	_	_
16	induce	_	_	VBP	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	mature	_	_	JJ	_	_	_	_	_
19	vascular	_	_	JJ	_	_	_	_	_
20	phenotype	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Gu	_	_	NNP	_	_	_	_	_
2	set	_	_	VBD	_	_	_	_	_
3	up	_	_	RP	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	protocol	_	_	NN	_	_	_	_	_
6	through	_	_	IN	_	_	_	_	_
7	which	_	_	WDT	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	after	_	_	IN	_	_	_	_	_
10	4	_	_	CD	_	_	_	_	_
11	days	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	treatment	_	_	NN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	VEGF	_	_	NNP	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	bFGF	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	he	_	_	PRP	_	_	_	_	_
20	produced	_	_	VBD	_	_	_	_	_
21	mature	_	_	JJ	_	_	_	_	_
22	ECs	_	_	NNP	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	only	_	_	RB	_	_	_	_	_
25	8	_	_	CD	_	_	_	_	_
26	days	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	cells	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	when	_	_	WRB	_	_	_	_	_
5	tested	_	_	VBN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	molecularly	_	_	RB	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	functionally	_	_	RB	_	_	_	_	_
11	similar	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	native	_	_	JJ	_	_	_	_	_
14	ECs	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Paik	_	_	NNP	_	_	_	_	_
2	et	_	_	FW	_	_	_	_	_
3	al.	_	_	FW	_	_	_	_	_
4	added	_	_	VBD	_	_	_	_	_
5	VEGF	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	bFGF	_	_	NNP	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	BMP4	_	_	NNP	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	already	_	_	RB	_	_	_	_	_
13	established	_	_	VBN	_	_	_	_	_
14	protocol	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	produce	_	_	VB	_	_	_	_	_
17	mature	_	_	JJ	_	_	_	_	_
18	ECs	_	_	NNP	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	hiPSCs	_	_	NNS	_	_	_	_	_
21	within	_	_	IN	_	_	_	_	_
22	12	_	_	CD	_	_	_	_	_
23	days	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	protocol	_	_	NN	_	_	_	_	_
4	requires	_	_	VBZ	_	_	_	_	_
5	more	_	_	JJR	_	_	_	_	_
6	time	_	_	NN	_	_	_	_	_
7	compared	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	other	_	_	JJ	_	_	_	_	_
10	ones	_	_	NNS	_	_	_	_	_
11	reported	_	_	VBN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	literature	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	aim	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	this	_	_	DT	_	_	_	_	_
19	study	_	_	NN	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	different	_	_	JJ	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	cells	_	_	NNS	_	_	_	_	_
6	were	_	_	VBD	_	_	_	_	_
7	used	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	draw	_	_	VB	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	RNA	_	_	NN	_	_	_	_	_
12	signature	_	_	NN	_	_	_	_	_
13	at	_	_	IN	_	_	_	_	_
14	different	_	_	JJ	_	_	_	_	_
15	stage	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	differentiation	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	last	_	_	JJ	_	_	_	_	_
3	step	_	_	NN	_	_	_	_	_
4	included	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	differentiation	_	_	NN	_	_	_	_	_
8	protocol	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	purification	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	positive	_	_	JJ	_	_	_	_	_
14	cells	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	step	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	essential	_	_	JJ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	fish	_	_	VB	_	_	_	_	_
7	out	_	_	RP	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	homogenous	_	_	JJ	_	_	_	_	_
10	subset	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	ensure	_	_	VB	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	safety	_	_	NN	_	_	_	_	_
18	needed	_	_	VBN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	future	_	_	JJ	_	_	_	_	_
22	cell	_	_	NN	_	_	_	_	_
23	implantation	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	engraftment	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Cell	_	_	NN	_	_	_	_	_
2	sorting	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	usually	_	_	RB	_	_	_	_	_
5	performed	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	using	_	_	VBG	_	_	_	_	_
8	magnetic	_	_	JJ	_	_	_	_	_
9	beads	_	_	NNS	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	surface	_	_	NN	_	_	_	_	_
13	specific	_	_	JJ	_	_	_	_	_
14	antibodies	_	_	NNS	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	adsorbed	_	_	VBN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	antibodies	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	directed	_	_	VBN	_	_	_	_	_
5	against	_	_	IN	_	_	_	_	_
6	mature	_	_	JJ	_	_	_	_	_
7	endothelial	_	_	JJ	_	_	_	_	_
8	markers	_	_	NNS	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	CD31	_	_	NNP	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	VE-cadherin	_	_	NNP	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	also	_	_	RB	_	_	_	_	_
16	known	_	_	VBN	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	CD144	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_

